Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment
Time to recurrence · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes time to recurrence (TTR), measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyHR 0.75 [0.31, 1.79]1 study · 150 participantsVery low